Associate Professor of Pathology, Brigham and Women's Hospital
Pathology
Dr. Lucian R. Chirieac, MD
|
|
Give Review
Lucian R. Chirieac, MD is an expert in the field of Pathology. Lucian Chirieac is also a published doctor. He has 69 paper published. The most recent paper is: NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Publications
- Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study.
- Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis.
- Clinicopathologic Characteristics of Malignant Mesotheliomas Arising in Patients With a History of Radiation for Hodgkin and Non-Hodgkin Lymphoma.
- Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group.
- p16 Deletion in Sarcomatoid Tumors of the Lung and Pleura.
- Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma.
- Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas.
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
- Nanoparticle Migration and Delivery of Paclitaxel to Regional Lymph Nodes in a Large Animal Model.
- Malignant pleural mesothelioma. Clinical practice guidelines in oncology.
- Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer.
- Paclitaxel-Eluting Polymer Film Reduces Locoregional Recurrence and Improves Survival in a Recurrent Sarcoma Model: A Novel Investigational Therapy.
- A comprehensive analysis of PAX8 expression in human epithelial tumors.
- Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
- Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer.
- The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
- Revolution in lung cancer: new challenges for the surgical pathologist.
- Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.
- Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.
- Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.
- Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films.
- Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases.
- A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
- Targeted Therapies in Lung Cancer.
- Prognostic significance of grading in lung adenocarcinoma.
- Second generation sequencing of the mesothelioma tumor genome.
- High-resolution computed tomography screening for lung cancer: unexpected findings and new controversies regarding adenocarcinogenesis.
- Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung.
- Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
- Amplification of chromosomal segment 4q12 in non-small cell lung cancer.
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
- Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
- Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
- Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
- Genome-wide analysis of survival in early-stage non-small-cell lung cancer.
- Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
- Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.
- A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
- HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
- Pathologic evaluation of malignant pleural mesothelioma.
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
- Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
- Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
- Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
- Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
- Transcriptome sequencing of malignant pleural mesothelioma tumors.
- Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.
- Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
- Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
- Glioblastoma in a patient with early-stage tonsil cancer.
- MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
- Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
- Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.
- Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a...
- Epithelioid hemangioendothelioma in a patient with unusual involvement of the rib and intercostal lymph nodes.
- Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
- The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
- Characterization of the myxoid variant of hibernoma.
- Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
- Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon car...
- Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
- Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
- Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation.
- Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
- Automated quantification of lymph node size and number in surgical specimens of stage II colorectal cancer.
- Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Doctors Specialties
- Pathology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
University of Rochester -
Carol Davila University of Medicine and Pharmacy
Hospital
-
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225064397 |
| Last Name Of The Provider | CHIRIEAC |
| First Name Of The Provider | LUCIAN |
| View All |
Similar Doctors
|
|
Dr. Xuefei Hong, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily E. Meserve, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George L. Mutter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith L. Ligon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Stefan Kraft, MD
This Doctor is OpenDoctor Recommended.
|